Genolution

Genolution Enterprise Value

The Enterprise Value (EV) of Genolution (225220.KQ) as of Oct 22, 2026 is 32.70 B KRW. In the previous year, Enterprise Value (EV) was 23.56 B KRW — a change of 38.78% (higher).

Enterprise Value

32.70 BKRW

YoY

38.78%

Last updated:

Enterprise Value (EV) of Genolution is 2025 32.70 B KRW. Enterprise Value (EV) of Genolution was 2024 23.56 B KRW. It decreases by 38.78% higher compared to the previous year.

The Genolution Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
29.13 B KRW
Jan 1, 2019
32.43 B KRW
Jan 1, 2020
-9.61 B KRW
Jan 1, 2021
-13.24 B KRW
Jan 1, 2022
1.38 B KRW
Jan 1, 2023
14.02 B KRW
Jan 1, 2024
23.56 B KRW
Jan 1, 2025
32.70 B KRW
The Genolution Enterprise Value history
YEAREnterprise ValueYoY
32.70 BKRW+38.78%
23.56 BKRW+68.09%
14.02 BKRW+915.70%
1.38 BKRW-110.43%
-13.24 BKRW+37.73%
-9.61 BKRW-129.63%
32.43 BKRW+11.35%
29.13 BKRW-4.64%
30.55 BKRW+0.57%
30.37 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Enterprise Value (EV) of Genolution is 32.70 B KRW in 2025.

Enterprise Value (EV) of Genolution changed from 23.56 B KRW to 32.70 B KRW, representing a 38.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Genolution since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s KRW, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' KRW varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genolution

All Key Metrics — Genolution